Hyaluronic Acid

CAS Number	9004-61-9 (hyaluronic acid); 9067-32-7 (sodium hyaluronate salt) — both live-verified
Chemical Class	Glycosaminoglycan — an unbranched polymer of repeating D-glucuronic acid and N-acetyl-D-glucosamine disaccharide units
Molecular Weight	Variable and functionally critical — from ~5 kDa to >2,000 kDa. MW is the key specification
Source	Endogenous (skin, synovial fluid, vitreous humour); commercial material by bacterial fermentation (Streptococcus) or from rooster comb
Typical Standardisation	Sodium hyaluronate purity by HPLC/carbazole assay; MW range must be specified separately
Primary Applications	Skin hydration (oral and topical); joint formulation; ophthalmic and dermal filler applications
Claim Strength (Overview)	Moderate for oral skin hydration (multiple RCTs, meta-analysed); High for topical humectancy
Buy from Herbuno	Hyaluronic Acid / Sodium Hyaluronate Powder →

Name origin: Hyaluronic acid takes its name from the hyaloid (vitreous) body of the eye, from which it was isolated in 1934, combined with uronic acid, one of its two constituent sugars. It is a glycosaminoglycan — an unbranched polymer of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine. Uniquely among glycosaminoglycans, it is not sulfated and is not attached to a protein core. Traditional use: None, and none should be manufactured. Hyaluronic acid was isolated in 1934 by Meyer and Palmer and is a product of 20th-century biochemistry. Its commercial life began in ophthalmic surgery and dermal fillers, moved to topical cosmetics, and only relatively recently to oral supplementation. Research trajectory: The scientifically interesting fact about hyaluronic acid — and the one that makes a purity figure nearly meaningless without more information — is that its biological behaviour is a function of molecular weight. High-molecular-weight HA is anti-inflammatory, space-filling, and immunosuppressive; low-molecular-weight fragments are pro-inflammatory and pro-angiogenic. These are opposite behaviours from the same polymer. Commercial source: Bacterial fermentation (typically Streptococcus species) is the dominant modern route, supplied as the more stable sodium salt.

---

Evidence for Hyaluronic Acid Applications

The oral skin evidence is more substantial than sceptics assume, and it has now been meta-analysed. A systematic review identified seven randomized controlled trials of oral hyaluronic acid supplementation and performed a meta-analysis comparing standardized mean differences between treatment and placebo groups across skin hydration, elasticity, firmness, wrinkle reduction, and transepidermal water loss (J Cosmet Dermatol 2025). Seven RCTs is a respectable evidence base for a cosmetic-adjacent supplement claim, and it is considerably more than most ingredients in this category can offer. Claim strength: Moderate.

The underlying trials are reasonably designed. A 12-week double-blinded, placebo-controlled trial of daily HA at 120 mg in 40 healthy Asian men and women aged 35–64 found skin condition significantly improved in wrinkle assessment, stratum corneum water content, transepidermal water loss, and elasticity in the HA group versus placebo, with wrinkle assessment, stratum corneum water content, and skin elasticity significantly improved from baseline versus placebo at both 8 and 12 weeks (Hsu 2021 Nutrients). Larger trials have since used 60–120 mg/day of 1.8 MDa sodium hyaluronate over 12 weeks in 150 adults with similar directionality. Claim strength: Moderate.

The mechanistic puzzle deserves honest acknowledgement rather than glossing. Hyaluronic acid is a very large polymer, and the obvious objection — that it cannot be absorbed intact and reach the dermis — is a serious one. Animal work has reported absorption, tissue affinity, and migration of dietary hyaluronan into skin, and one proposal is that HA is depolymerised by gut microbiota into smaller fragments that are absorbed and either reach the skin or act as signalling molecules; another is that gut-local effects on immune signalling mediate the benefit. The trials show an effect; the mechanism is not settled, and a supplier who claims otherwise is inventing certainty. Claim strength: Emerging (mechanism).

Molecular weight is the specification that matters, and most certificates do not state it. HA molecular weight spans from around 5 kDa to over 2,000 kDa, and biological behaviour inverts across that range: high-MW HA (>1,000 kDa) is anti-inflammatory, immunosuppressive, and space-filling; low-MW fragments (<200 kDa) are pro-inflammatory and pro-angiogenic, and are recognised by innate immune receptors as danger signals. A buyer purchasing "hyaluronic acid" without an MW specification has not specified the ingredient. The oral trials have used both — 1.8 MDa in one, 800 k and 300 k in another — and reported benefit, which is itself interesting, but the MW must be stated and matched to the intended application. Claim strength: High (established structure-function).

The topical and device applications rest on entirely different and much firmer footing, and should not be confused with the oral claim. Topically, HA is a humectant of extraordinary capacity — it binds many times its weight in water — and its skin-surface hydration effect is straightforward physical chemistry rather than a physiological claim; note, though, that high-MW HA does not penetrate the stratum corneum and works at the surface. In ophthalmic surgery and dermal fillers, HA is a regulated medical device or drug, and that evidence has no bearing on a supplement claim. Claim strength: High (topical humectancy).

---

Dosage & Formulator Specification

Herbuno carries Hyaluronic Acid / Sodium Hyaluronate powder. Buyers must specify the required molecular weight range — this is the determinative specification for this ingredient and is not captured by a purity figure. Herbuno will discuss MW requirements at enquiry.

Oral trial dosing has centred on 120 mg/day over 12 weeks, with a larger recent trial using 60 and 120 mg/day of 1.8 MDa material and noting emerging evidence for efficacy at substantially lower dosages (25–80 mg/day) in other therapeutic areas. Benefit in the trials emerged over 8–12 weeks rather than acutely, which should be reflected in label expectations. For topical applications, use levels are governed by the desired rheology and humectancy and are a formulation rather than a dose question.

Analytical verification must specify molecular weight distribution — not merely an average, since a broad distribution containing low-MW fragments carries different biology than a narrow high-MW material — alongside sodium hyaluronate purity (HPLC or carbazole assay for glucuronic acid content), protein and nucleic acid residuals (critical for fermentation-derived material), and endotoxin, which is essential for any application near mucosa or for injectable-grade material. Production route (bacterial fermentation versus rooster comb) should be documented; rooster-comb material carries avian allergen and is generally being displaced. Fermentation strain and downstream purification should be stated.

Hyaluronic acid is endogenous to the human body, is well tolerated orally and topically, and has an extensive safety record across food, cosmetic, and medical-device use. Three notes. Rooster-comb-derived material carries avian protein allergen risk and should be declared; fermentation-derived material avoids this and is the modern default. Because low-molecular-weight HA fragments are recognised by innate immune receptors as pro-inflammatory danger signals, a poorly characterised or degraded material is not merely less effective but potentially differently active — this is a real argument for MW specification rather than a theoretical one. Finally, the injectable and dermal-filler applications of HA are regulated medical procedures with their own risk profile and have no relationship to an oral supplement; the two should never be conflated in marketing.

---

Frequently Asked Questions — Hyaluronic Acid

Does oral hyaluronic acid actually reach the skin?
The trials show an effect; the mechanism is not settled, and anyone claiming certainty is inventing it. A meta-analysis of seven RCTs found benefit across hydration, elasticity, and wrinkle depth. But HA is a very large polymer, and how it works is debated — possibly gut-microbiota depolymerisation into absorbable fragments, possibly gut-local immune signalling.

Why does molecular weight matter so much?
Because the biology inverts across the range. High-MW HA (>1,000 kDa) is anti-inflammatory, immunosuppressive, and space-filling. Low-MW fragments (<200 kDa) are pro-inflammatory and pro-angiogenic, recognised by innate immune receptors as danger signals. A buyer who purchases "hyaluronic acid" without an MW specification has not specified the ingredient.

What dose is used in the oral trials?
Typically 120 mg/day over 12 weeks, with a larger recent trial using 60 and 120 mg/day of 1.8 MDa sodium hyaluronate. Benefit emerged over 8-12 weeks rather than acutely. There is emerging evidence for efficacy at lower doses (25-80 mg/day) in other therapeutic areas.

Is dermal filler evidence relevant to a supplement?
No, and conflating them would be misleading. Injectable HA fillers and ophthalmic HA are regulated medical devices or drugs with their own evidence and risk profile. That has no bearing whatever on an oral supplement claim, and marketing that borrows the credibility of one for the other is not honest.

Related compounds: Glucosamine, Collagen, Polysaccharides, Aloe Polysaccharides

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery